EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study

Lvchang Zhu, Xinxin Zeng, Yuhang Wu, Xuben Yu, Shanshan Xu, Qiuxia Wang, Xiaoshan Zhang, Xi Zhang, Qiang Shu, Zihao Yang iD, Lisu Huang iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00294-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Lvchang Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangz…. Hauptthemen laut MEDLINE: Linezolid, Anti-Bacterial Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the widespread pediatric use of linezolid, data on its hematologic toxicity—particularly among children exposed to anticancer chemotherapy—remain limited and inconsistent. This study aimed to evaluate linezolid-induced hematotoxicity through pharmacokinetic analysis, with an emphasis on chemotherapy-exposed pediatric patients. This dual-center prospective study assessed linezolid pharmacokinetics and clinical profiles in chemotherapy-stratified pediatric cohorts, examining associations with hematologic toxicity. Among 229 pediatric patients (65 with cancer), hematologic toxicity occurred in 43.2%, with significantly higher risks of leukopenia (hazard ratio [HR] 20.29, 95% confidence interval [CI]: 3.98–103.38), neutropenia (HR 2.60, 95% CI: 1.00–6.77), and thrombocytopenia events (HR 7.08, 95% CI: 2.19–22.92) in cancer patients. Median linezolid trough and peak concentrations were 2.60 mg/L (interquartile range [IQR] 1.42–4.06) and 12.00 mg/L (IQR 9.5–14.19), respectively. Among cancer patients, trough concentrations above 7 mg/L elevated leukopenia (HR 6.33, 95% CI: 1.36–29.42) and anemia event (HR 8.72, 95% CI: 1.98–38.37) risk. Prolonged therapy exceeding 14 days elevated the risk of anemia events (HR 2.17; 95% CI: 1.08–4.35), while durations beyond 28 days also increased the risk of neutropenia events (HR 3.58; 95% CI, 1.37–9.32). At equivalent daily doses, twice-daily dosing resulted in higher peak concentrations (19.65 vs 13.67 mg/L; P = 0.020) and a greater incidence of anemia events (62.50% vs 25.00%; P = 0.033) compared to thrice-daily regimens. Linezolid frequently causes hematologic toxicity in children, particularly in chemotherapy recipients. Risk is also driven by high concentrations (peak > 15 mg/L, trough > 7 mg/L in cancer patients), prolonged therapy, and twice-daily dosing, necessitating careful monitoring and dose optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidAnti-Bacterial AgentsHumansMaleFemaleChildProspective StudiesChild, PreschoolNeutropeniaNeoplasmsLeukopeniaAdolescentThrombocytopeniaInfantAntineoplastic Agents

Stichwörter der Autor:innen

anti-cancer chemotherapyhematologic toxicitylinezolidpediatricpharmacokineticstherapeutic drug monitoring

Substanzen

LinezolidAnti-Bacterial AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Pediatric Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
  • Department of Infectious Diseases, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Infectious Disease, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Clinical Research Unit, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic and Cardiovascular Surgery, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.

ORCID-Profile: Zihao Yang, Lisu Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, L., Zeng, X., Wu, Y., Yu, X., Xu, S., Wang, Q., Zhang, X., Zhang, X., Shu, Q., Yang, Z., & Huang, L. (2025). Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00294-25

Vancouver

Zhu L, Zeng X, Wu Y, Yu X, Xu S, Wang Q, et al. Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00294-25

BibTeX
@article{Zhu2025,
  author = {Zhu, Lvchang and Zeng, Xinxin and Wu, Yuhang and Yu, Xuben and Xu, Shanshan and Wang, Qiuxia and Zhang, Xiaoshan and Zhang, Xi and Shu, Qiang and Yang, Zihao and Huang, Lisu},
  title = {Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00294-25}
}
Kostenlos starten →